Moelis & Company Announces the Appointments of Arek Kurkciyan and Dennis Crandall as Managing Directors, Expanding the Firm’s Healthcare Franchise

New York, October 18, 2022

Moelis & Company today announced the appointments of Arek Kurkciyan and Dennis Crandall as Managing Directors providing strategic and financial advice to clients in the life sciences and outsourced pharmaceutical services sectors. Based in New York, they will join Moelis & Company’s growing healthcare team on November 22, 2022.

Arek and Dennis bring extensive investment banking experience, having helped clients respond to some of the most significant shifts in the pharmaceutical landscape.  These include a particular focus on mergers and acquisitions that facilitate the convergence of the life sciences and outsourced pharmaceutical services industries, as well as the rise of new technologies that fuel the development of cutting-edge therapies.

Arek joins from Morgan Stanley where most recently he was a Managing Director in the Healthcare Investment Banking group. Previously he held investment banking roles at Deutsche Bank, and he began his career with various roles in the pharmaceutical industry at GlaxoSmithKline and Novartis.

Dennis was previously a Managing Director at Morgan Stanley in the Healthcare Investment Banking group. Prior to that, he worked on the M&A team at UBS Investment Bank. Earlier in his career, he held various roles at KPMG and was an investment analyst at Jacobsen Capital Management.

“The explosion of innovation in biologics, including cell and gene therapies, represents a significant source of growth for both corporates and sponsors in the life sciences sector and beyond.  Robust continued investment in expanding R&D and production expertise should continue to drive M&A activity and reshape the healthcare landscape,” said Jeff Raich, Co-President of Moelis & Company. “Arek and Dennis bring strong relationships with both large-cap corporates and private equity investors that are core to our Firm’s strategy.  Their addition to our collaborative platform expands the high quality, bespoke advice we can offer not only our healthcare clients, but also those across a diverse range of industries with a broad and strategic interest in the life sciences.”

About Moelis & Company

Moelis & Company is a leading global independent investment bank that provides innovative strategic advice and solutions to a diverse client base, including corporations, governments and financial sponsors.  The Firm assists its clients in achieving their strategic goals by offering comprehensive integrated financial advisory services across all major industry sectors.  Moelis & Company’s experienced professionals advise clients on their most critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters.  The Firm serves its clients from 21 locations in North and South America, Europe, the Middle East, Asia and Australia.  For further information, please visit: or follow us on Twitter @Moelis.